Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer Pathogenesis

NCT ID: NCT03173001

Last Updated: 2023-03-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer (CRC) has the third highest cancer incidence in the world. There is mounting evidence that the intestinal microbiota plays an important role in colorectal carcinogenesis. but there is no information on protozoa of intestinal microbiota except Blastocystis hominis, although data on this issue is scarce. In this study we are going to evaluate the prevalence of intestinal helminthes and protozoa in CRC patients and control group that includes random residents. Patients will be examined before, after surgery and chemotherapy. Parasites and protozoan infection intensity will be estimated by triple coproscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted on the basis of Research Institute of Epidemiology, Microbiology and Infectious Diseases and Research Center of Oncology, Ministry of Public Health of the Republic of Uzbekistan.

All the CRC patients from Research Center of Oncology will be examined with their written concent. Diagnosis of CRC is based on the results of clinical examination, endoscopic, histological, X-ray and laboratory data according to International Classification proposed by the American Joint Committee on Cancer (AJCC) with application TNM (T-tumor, N-nodus, M-metastases) for diagnosis. Descriptors in T (primary tumor) mean the degree of the tumor spreading in layers of the intestine; descriptors in N mean absence of metastases or the number of lymph nodes with metastases; descriptors in M shows absence or presence of remote metastases.

The control group will be a random residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with CRC. Age of individuals under examination will be taken at the range from 17 to 90 years old.

Collection of stool samples Three stool samples for parasitological examination will be taken from both control subjects and CRC patients at 1-2 days interval. Stool samples were collected in individual containers, containing 5 ml of Turdiev's preservative provided conservation and staining of protozoa cysts and eggs of worms for a year. The Turdiev's preservative includes:80 ml of 0.2% aqueous solution of sodium nitrite, 10 ml of formaldehyde, 2 ml of glycerin, 8 ml of Lugol's solution, 250 ml of distilled water.

Collection of material for C. parvum (Cryptosporidium parvum) detection in stool samples will be carried out by preparation of fresh feces thin smears.

Stool samples examination Parasitological diagnosis will be performed by triple coproscopy using formalin - ethyl acetate concentration technique. For preparations staining Lugol's solution was used. The intensity of protozoa will be estimated by the number of protozoa in the field of view (ocular x10, objective x40), the number of protozoa will be calculated at least in 10 fields of view. 1-2, 3-4 and 5-6 microorganisms in a field of view were considered as infection of low, mean and high intensity respectively.

Modified Ziehl- Neelsen method will be used for staining and detection of C. parvum preparations. The stained smears will be observed with ×100 oil immersion lens for the presence of C. parvum.

Parasitological examination of the additional group of the patients obtained chemotherapy will be carried out before and after surgery and complete course of chemotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Colorectal Cancer Metastatic Intestinal Parasite Protozoan Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with colorectal cancer

Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.

Parasitological examination

Intervention Type DIAGNOSTIC_TEST

Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Population

The control group includes residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with colorectal cancer.

Parasitological examination

Intervention Type DIAGNOSTIC_TEST

Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Patients with CRC without metastases

Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.

Parasitological examination

Intervention Type DIAGNOSTIC_TEST

Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Patients with CRC with metastases

Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.

Parasitological examination

Intervention Type DIAGNOSTIC_TEST

Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Patients with CRC before operation

Patients hospitalized with colorectal cancer before operation at the Department of Coloproctology of Republican Oncology Research Center.

Parasitological examination

Intervention Type DIAGNOSTIC_TEST

Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Patients with CRC after operation

Patients hospitalized with colorectal cancer after operation at the Department of Coloproctology of Republican Oncology Research Center.

Parasitological examination

Intervention Type DIAGNOSTIC_TEST

Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Patients with CRC before chemotherapy

Patients hospitalized with colorectal cancer before operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.

Parasitological examination

Intervention Type DIAGNOSTIC_TEST

Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Patients with CRC after chemotherapy

Patients hospitalized with colorectal cancer after operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.

Parasitological examination

Intervention Type DIAGNOSTIC_TEST

Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Parasitological examination

Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Coproscopy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients with colorectal cancer before, after surgery and chemotherapy.

For control group:

* Includes all individuals that doesn't have any complaints from gastrointestinal tract

Exclusion Criteria

* Age before 18.
* Patients with other gastrointestinal disorders
* Patients with any chronic concomitant diseases
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Svetlana Osipova, MD, PhD, DS

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

References

Explore related publications, articles, or registry entries linked to this study.

Toychiev A, Abdujapparov S, Imamov A, Navruzov B, Davis N, Badalova N, Osipova S. Intestinal helminths and protozoan infections in patients with colorectal cancer: prevalence and possible association with cancer pathogenesis. Parasitol Res. 2018 Dec;117(12):3715-3723. doi: 10.1007/s00436-018-6070-9. Epub 2018 Sep 15.

Reference Type RESULT
PMID: 30220046 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ADCC 15 21 2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.